2022 中国台湾专家共识:新生血管性年龄相关性黄斑变性的治疗和延长方案实施的最佳方法和标准

2022-01-15 中国眼科相关专家组(统称) BMC Ophthalmol

随着抗NEGF药物的出现,新生血管性年龄相关性黄斑变性(nAMD)的治疗向前迈进了一大步。本文主要针对nAMD治疗和延长方案实施的最佳方法和标准提供指导建议。

中文标题:

2022 中国台湾专家共识:新生血管性年龄相关性黄斑变性的治疗和延长方案实施的最佳方法和标准

英文标题:

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan

发布日期:

2022-01-15

简要介绍:

随着抗NEGF药物的出现,新生血管性年龄相关性黄斑变性(nAMD)的治疗向前迈进了一大步。本文主要针对nAMD治疗和延长方案实施的最佳方法和标准提供指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2022 中国台湾专家共识:新生血管性年龄相关性黄斑变性的治疗和延长方案实施的最佳方法和标准.pdf)] GetToolGuiderByIdResponse(projectId=1, id=012c21c0023255bb, title=2022 中国台湾专家共识:新生血管性年龄相关性黄斑变性的治疗和延长方案实施的最佳方法和标准, enTitle=Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan, guiderFrom=BMC Ophthalmol, authorId=0, author=, summary=随着抗NEGF药物的出现,新生血管性年龄相关性黄斑变性(nAMD)的治疗向前迈进了一大步。本文主要针对nAMD治疗和延长方案实施的最佳方法和标准提供指导建议。, cover=https://img.medsci.cn/2022118/1642509454363_1608702.jpg, journalId=0, articlesId=null, associationId=1043, associationName=中国眼科相关专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sat Jan 15 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">随着抗NEGF药物的出现,新生血管性年龄相关性黄斑变性(nAMD)的治疗向前迈进了一大步。本文主要针对nAMD治疗和延长方案实施的最佳方法和标准提供指导建议。</span></p>, tagList=[TagDto(tagId=1788, tagName=黄斑变性), TagDto(tagId=2541, tagName=视网膜), TagDto(tagId=66391, tagName=新生血管性年龄相关性黄斑变性)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6562, appHits=89, showAppHits=0, pcHits=526, showPcHits=6473, likes=1, shares=9, comments=6, approvalStatus=1, publishedTime=Tue Jan 18 20:30:54 CST 2022, publishedTimeString=2022-01-15, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Tue Jan 18 20:39:45 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 06:31:12 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 中国台湾专家共识:新生血管性年龄相关性黄斑变性的治疗和延长方案实施的最佳方法和标准.pdf)])
2022 中国台湾专家共识:新生血管性年龄相关性黄斑变性的治疗和延长方案实施的最佳方法和标准.pdf
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1224345, encodeId=cedf122434579, content=简要介绍里面写错了吧?是抗VEGF药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33095424404, createdName=查文献啊查文献, createdTime=Sat Jun 04 08:52:02 CST 2022, time=2022-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189601, encodeId=46a0118960107, content=学习借鉴<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3fa6482137, createdName=ms9000001995137444, createdTime=Tue Feb 01 21:46:41 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187596, encodeId=0e55118e5967a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Jan 24 07:22:22 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185956, encodeId=aae81185956f4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Wed Jan 19 10:37:25 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185882, encodeId=e89211858822e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:30:40 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
    2022-06-04 查文献啊查文献

    简要介绍里面写错了吧?是抗VEGF药物

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1224345, encodeId=cedf122434579, content=简要介绍里面写错了吧?是抗VEGF药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33095424404, createdName=查文献啊查文献, createdTime=Sat Jun 04 08:52:02 CST 2022, time=2022-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189601, encodeId=46a0118960107, content=学习借鉴<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3fa6482137, createdName=ms9000001995137444, createdTime=Tue Feb 01 21:46:41 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187596, encodeId=0e55118e5967a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Jan 24 07:22:22 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185956, encodeId=aae81185956f4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Wed Jan 19 10:37:25 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185882, encodeId=e89211858822e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:30:40 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
    2022-02-01 ms9000001995137444

    学习借鉴#学习#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1224345, encodeId=cedf122434579, content=简要介绍里面写错了吧?是抗VEGF药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33095424404, createdName=查文献啊查文献, createdTime=Sat Jun 04 08:52:02 CST 2022, time=2022-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189601, encodeId=46a0118960107, content=学习借鉴<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3fa6482137, createdName=ms9000001995137444, createdTime=Tue Feb 01 21:46:41 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187596, encodeId=0e55118e5967a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Jan 24 07:22:22 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185956, encodeId=aae81185956f4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Wed Jan 19 10:37:25 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185882, encodeId=e89211858822e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:30:40 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
    2022-01-24 胡国宏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1224345, encodeId=cedf122434579, content=简要介绍里面写错了吧?是抗VEGF药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33095424404, createdName=查文献啊查文献, createdTime=Sat Jun 04 08:52:02 CST 2022, time=2022-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189601, encodeId=46a0118960107, content=学习借鉴<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3fa6482137, createdName=ms9000001995137444, createdTime=Tue Feb 01 21:46:41 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187596, encodeId=0e55118e5967a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Jan 24 07:22:22 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185956, encodeId=aae81185956f4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Wed Jan 19 10:37:25 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185882, encodeId=e89211858822e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:30:40 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
    2022-01-19 屋顶瞄爱赏月

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1224345, encodeId=cedf122434579, content=简要介绍里面写错了吧?是抗VEGF药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33095424404, createdName=查文献啊查文献, createdTime=Sat Jun 04 08:52:02 CST 2022, time=2022-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189601, encodeId=46a0118960107, content=学习借鉴<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3fa6482137, createdName=ms9000001995137444, createdTime=Tue Feb 01 21:46:41 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187596, encodeId=0e55118e5967a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Jan 24 07:22:22 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185956, encodeId=aae81185956f4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Wed Jan 19 10:37:25 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185882, encodeId=e89211858822e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:30:40 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
    2022-01-19 微探

    学习学习

    0